Pro-haemorrhagic effects of calcium antagonists: A comparison of isradipine and atenolol on ex vivo platelet function in hypertensive subjects

Journal of Human Hypertension

Volumn 11, Issue 12, 1997, Pages 783-788

  Smith, A ^a   McPherson, J ^a   Taylor, M ^a   Mason, A ^a   Carney, S ^a,b   Gillies, A ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b Hunter Region Mail Centre   (Australia)

Author keywords

Calcium channel blocking drugs; Platelet function; blocking drugs

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA THROMBOGLOBULIN; CALCIUM ANTAGONIST; CHOLESTEROL; COLLAGEN; ISRADIPINE; LIPID; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; EUGLOBULIN LYSIS TEST; FEMALE; FIBRINOLYSIS; GENERAL PRACTICE; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MALE; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TIME;

EID: 0031468008     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000449     Document Type: Article

References (27)

1. Furberg CD, Psaty BM and Meyer JV. Nifedipine: dose related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-1331.
2. Psaty BM et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-625.
3. Pahor M et al. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 9: 695-699.
4. Pahor M et al. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996; 347: 1061-1065.
5. Fitscha P et al. Effects of isradipine on platelet function in hypertension at rest and during exercise. Am J Hypertens 1991; 4 (Suppl): 1785-1805.
6. Addonizio VP et al. Effects of verapamil and diltiazem on human platelet function. Am J Physiol 1986; 250: H366-371.
7. Anfossi G et al. Calcium-channel blocking agents verapamil and diltiazem are inhibitors of vasopressin-induced human platelet activation. Clin Exp Pharmacol Physiol 1991; 18: 767-773.
8. Altman R, Scazziota A, Dujovne C. Diltiazem potentiates the inhibitory effect of aspirin on platelet aggregation. Clin Pharmacol Therapeut 1988; 44: 320-325.
9. Ding Y-A et al. Effect of isradipine on platelet aggregation and oxygen free radicals in hypertension. J Hypertens 1991; 9: S370-371.
10. McPherson J, Zucher MB. Platelet retention in glass bead columns: adhesion to glass and subsequent platelet-platelet interactions. Blood 1976; 47: 55-67.
11. Sinzinger H, Weiss K, Fitscha P. Isradipine is a potent calcium antagonist on platelet function and the prostaglandin system. Thromb Haemost 1990; 62: 551.
12. Fetkovska N et al. Serotonin and platelet activation during treatment with isradipine. J Cardiovasc Pharmacol 1991; 18: S31-33.
13. Fetkovska N et al. Platelet activating effect of low-density lipoprotein and its reversal by isradipine. Am J Hypertens 1991; 4: 175S-177S.
14. Tison P et al. Effects of dihydropyridines and their combination with aspirin on blood pressure and circadian platelet activity in patients with essential hypertension. Am J Hypertens 1994; 7: 46S-49S.
15. Sinzinger H et al. Isradipine improves platelet function in hypertensives. Eur J Clin Pharmacol 1992; 42: 43-46.
16. Gleerup G, Mehlsen J, Winther K. Does calcium channel blockade and beta-adrenergic blockade affect platelet function and fibrinolysis to a varying degree? J Cardiovasc-Pharmacol 1995; 25: 87-89.
17. Klauser R et al. Platelet aggregation and metabolic control are not affected by calcium antagonist treatment in type II diabetes mellitus. J Cardiovasc Pharmacol 1990; 15: S93-96.
18. Islim IF, Beevers DG, Bareford D. The effect of antihypertensive drugs on in vivo platelet activity in essential hypertension. J Hypertens 1992; 10: 379-383.
19. Mazeavd MM et al. Hypercholesterolaemia modulates the effects of nitrendipine on blood pressure and platelet function in essential hypertension. J Cardiovasc Pharmacol 1991; 18 (Suppl 10): S32-35.
20. Belousov Y, Kushnaryov V. The effects of nisoldipine, diltiazem, nifedipine, and verapamil on haemodynamic parameters and red blood cells - platelet interactions in patients with arterial hypertension. J Cardiovasc Pharmacol 1991; 18 (Suppl 9): S32-35.
21. Ding YA, Law HW, Chou TL. Comparison of cilazapril and nifedipine retard on ambulatory blood pressure, metabolic, rheological and platelet function in hypertensive patients. J Hum Hypertens 1994; 8: 137-143.
22. Ding YA, Chou TC, Lin KC. Effects of long acting propranolol and verapamil on blood pressure, platelet function metabolic and rheological properties in hypertension. J Hum Hypertens 1994; 8: 273-278.
23. Chou TZ, Lee KW, Ding YA. Effect of felodipine-ER on blood pressure, platelet function, and rheological properties in hypertension. Can J Cardiol 1993; 9: 423-427.
24. Wilson J et al. Treatment of hypertension induces a fall in platelet cytoplasmic calcium concentration without influencing platelet aggregation. Thromb Haemost 1992; 68: 683-686.
25. Zucker ML et al. Effect of diltiazem and low dose aspirin on platelet aggregation and ATP release induced by paired agonists. Thromb Haemost 1993; 70: 332-335.
26. Ding YA, Chang SM, Chou TC. Comparison of amlodipine and quinalapril on ambulatory blood pressure and platelet function in hypertension. J Hum Hypertens 1995; 9: 637-641.
27. Pales J et al. Effects of dihydropyridines and inorganic calcium blockers on aggregation and on intracellular free calcium in platelets. Biochem Biophys Acta 1991; 1064: 169-174.